RECOVERY trial

  • Research type

    Research Study

  • Full title

    Randomised Evaluation of COVID-19 Therapy (RECOVERY)

  • IRAS ID

    281712

  • Contact name

    Peter Horby

  • Contact email

    peter.horby@ndm.ox.ac.uk

  • Sponsor organisation

    University of Oxford

  • Eudract number

    2020-001113-21

  • ISRCTN Number

    ISRCTN50189673

  • Duration of Study in the UK

    10 years, 6 months, 11 days

  • Research summary

    Background: In early 2020, as this protocol was being developed, there were no approved treatments for COVID-19, a disease induced by the novel coronavirus SARS-CoV-2 that emerged in China in late 2019. The UK New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG) advised that several possible treatments should be evaluated, including Lopinavir-Ritonavir, Interferon β, corticosteroids, and Remdesivir. These groups also advised that other treatments will soon emerge that require evaluation. A World Health Organization (WHO) expert group issued broadly similar advice.

    Eligibility and randomisation: This protocol describes a randomised trial among adults hospitalised for confirmed COVID-19. Eligible patients are randomly allocated between several treatment arms, each to be given in addition to the usual standard of care in the participating hospital: No additional treatment vs Lopinavir-Ritonavir vs low-dose corticosteroids vs hydroxychloroquine vs azithromycin. For patients for whom not all the trial arms are appropriate or at locations where not all are available, randomisation will be between fewer arms.

    Outcomes: The main outcomes will be death within 28 days of randomisation, discharge, and need for ventilation. For the main analyses, follow-up will be censored at 28 days after admission. Additional information on longer term outcomes may be collected through review of medical records or linkage to medical databases such as those managed by NHS Digital and equivalent organisations in the devolved nations.

    Outcomes: The main outcomes will be in-hospital death, discharge, and need for ventilation. For the main analyses, follow-up will be censored at 28 days after admission. Additional information on longer term outcomes may be collected through review of medical records or linkage to medical databases such as those managed by NHS Digital and equivalent organisations in the devolved nations.

  • REC name

    East of England - Cambridge East Research Ethics Committee

  • REC reference

    20/EE/0101

  • Date of REC Opinion

    17 Mar 2020

  • REC opinion

    Favourable Opinion